June 24, 2019 / 5:14 AM / a month ago

BRIEF-Santhera Says UK agency Renews EAMS Opinion For Santhera’S Idebenone In Duchenne Muscular Dystrophy

June 24 (Reuters) - Santhera Pharmaceuticals Holding AG :

* SAYS UK’S MHRA RENEWS EAMS SCIENTIFIC OPINION FOR SANTHERA’S IDEBENONE IN DUCHENNE MUSCULAR DYSTROPHY

* SAYS UK’S MHRA HAS RENEWED FOR A FURTHER YEAR THE EARLY ACCESS TO MEDICINES SCHEME (EAMS) SCIENTIFIC OPINION FOR IDEBENONE FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) IN RESPIRATORY FUNCTION DECLINE WHO ARE NOT TAKING GLUCOCORTICOIDS Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below